U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07486089) titled 'Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)' on March 17.
Brief Summary: This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Study Start Date: Feb. 02
Study Type: INTERVENTIONAL
Condition:
Breast Cancer (Locally Adv...